The 2016 WHO classification of tumours of the central nervous system: the major points of revision
T Komori - Neurologia medico-chirurgica, 2017 - jstage.jst.go.jp
The updated 2016 edition of the World Health Organization (WHO) Classification of Tumours
of the Central Nervous System (CNS) uses molecular parameters and the histology to define …
of the Central Nervous System (CNS) uses molecular parameters and the histology to define …
Metformin with temozolomide for newly diagnosed glioblastoma: Results of phase i study and a brief review of relevant studies
Simple Summary Glioblastoma is an incurable disease, demanding new therapeutic
approaches. Our preclinical studies proved that the antidiabetic drug metformin could induce …
approaches. Our preclinical studies proved that the antidiabetic drug metformin could induce …
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
H Arita, K Yamasaki, Y Matsushita, T Nakamura… - Acta neuropathologica …, 2016 - Springer
The prognostic impact of TERT mutations has been controversial in IDH-wild tumors,
particularly in glioblastomas (GBM). The controversy may be attributable to presence of …
particularly in glioblastomas (GBM). The controversy may be attributable to presence of …
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
K Fukuoka, Y Kanemura, T Shofuda… - Acta neuropathologica …, 2018 - Springer
Extensive molecular analyses of ependymal tumors have revealed that supratentorial and
posterior fossa ependymomas have distinct molecular profiles and are likely to be different …
posterior fossa ependymomas have distinct molecular profiles and are likely to be different …
TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations
H Arita, Y Matsushita, R Machida, K Yamasaki… - Acta neuropathologica …, 2020 - Springer
TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated
gliomas. However, whether these mutations have an impact on patient survival independent …
gliomas. However, whether these mutations have an impact on patient survival independent …
Integrated multi-omic analysis of esthesioneuroblastomas identifies two subgroups linked to cell ontogeny
Esthesioneuroblastoma (ENB) is a rare cancer of the olfactory mucosa, with no established
molecular stratification to date. We report similarities of ENB with tumors arising in the neural …
molecular stratification to date. We report similarities of ENB with tumors arising in the neural …
[HTML][HTML] Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult …
K Satomi, M Ohno, Y Matsushita, M Takahashi… - Modern Pathology, 2021 - Elsevier
Homozygous deletion (HD) of CDKN2A is one of the most promising biomarkers for
predicting poor prognosis of IDH-mutant diffuse gliomas. The Consortium to Inform …
predicting poor prognosis of IDH-mutant diffuse gliomas. The Consortium to Inform …
Immunohistochemical profiles of I DH 1, MGMT and P 53: Practical significance for prognostication of patients with diffuse gliomas
R Ogura, Y Tsukamoto, M Natsumeda… - …, 2015 - Wiley Online Library
Genetic and epigenetic status, including mutations of isocitrate dehydrogenase (IDH) and
TP 53 and methylation of O 6‐methylguanine‐DNA methyltransferase (MGMT), are …
TP 53 and methylation of O 6‐methylguanine‐DNA methyltransferase (MGMT), are …
miR-378a-3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17
XB Guo, XC Zhang, P Chen, LM Ma… - Oncology …, 2019 - spandidos-publications.com
Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor and
patients with this disease tend to have poor clinical outcome. MicroRNAs (miRs) are …
patients with this disease tend to have poor clinical outcome. MicroRNAs (miRs) are …
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
K Ichimura, Y Narita, CE Hawkins - Acta Neuropathologica, 2015 - Springer
Diffusely infiltrating astrocytomas include diffuse astrocytomas WHO grade II and anaplastic
astrocytomas WHO grade III and are classified under astrocytic tumours according to the …
astrocytomas WHO grade III and are classified under astrocytic tumours according to the …